BioMarin Pharmaceutical, Inc.

BioMarin Pharmaceutical, Inc.

BioMarin Pharmaceutical, Inc.

Overview
Date Founded

1996

Headquarters

770 Lindaro Street, San Rafael, CA, 94901, USA

Type of Company

Public

Employees (Worldwide)

3,001

Industries

Biotechnology
Industrial Machinery & Manufacturing

Company Description

About BioMarin BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; KUVAN® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers and BMN-111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia.

Contact Data
Trying to get in touch with decision makers at BioMarin Pharmaceutical, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer & President

Acting Chief Executive Officer

Executive Vice President & Chief Financial Officer

Executive Vice President, General Counsel & Secretary

Executive Vice President & Chief Commercial Officer

Senior Vice President, Chief Compliance Officer

Chief Information Officer

Chief Scientific Strategy Officer

Chief Technical Officer

Chief Accounting Officer & Group Vice President

Board of Directors

President at International Council of Ophthalmology Foundation

Professor & Executive Director-Personalized Health at University of Utah Health Sciences Center

Principal at PureSight Advisory LLC

Chief Executive Officer & President at BioMarin Pharmaceutical, Inc.

Venture Partner at Pappas Capital LLC

Venture Partner Healthcare at Qiming Venture Partners Ltd.

Chief Financial Officer & Executive Vice President at Intersect ENT, Inc.

Director at Reform Biologics LLC

Director at Labcyte, Inc.

Paths to BioMarin Pharmaceutical, Inc.
Potential Connections via
Relationship Science
You
BioMarin Pharmaceutical, Inc.
Owners & Shareholders
Details Hidden

CWGI is the investment adviser to the American Funds Group, a family of 30 funds marketed to individuals exclusively through financial advisers and other intermediaries. American Funds are also used as investment vehicles for 401ks, other retirement plans, variable annuities and 529 college savings plans. The funds have the following characteristics: (1) a long-term, value-oriented approach; (2) long-established, global research; (3) a multiple portfolio counselor system that combines teamwork with individual accountability; (4) experienced, long-tenured investment professionals; and (5) a commitment to low operating expenses, among the lowest in the fund industry. CWGI uses a Multiple Portfolio Counselor System wherein the assets of each fund are divided into smaller, more manageable portions. Research analysts typically manage a segment as well, bringing their expertise directly to bear on the fund's results and portfolio counselors are free to make their own decisions. Investment decisions are based on internal research.

Details Hidden

PRIMECAP Management aims to provide superior long-term investment results by utilizing fundamental research and bottom-up stock picking to construct portfolios. The firm looks for stocks that will outperform the market over a three to five-year horizon. PRIMECAP Management does not have a committee or small group that decides on whether or not to invest in an idea. Each portfolio manager makes an individual decision whether or not to invest in new ideas.

Details Hidden

Dodge & Cox employs in-house, fundamental bottom-up research, a rigorous valuation discipline, and maintains a long-term investment horizon. Their investment decisions are made by a team of seasoned investment professionals. The firm’s approach stresses an evaluation of risk relative to opportunity and they seek investments that they believe are undervalued by the market.

Recent Transactions
Details Hidden

BioMarin Pharmaceutical, Inc. issued USD Common Stock

Details Hidden

BioMarin Pharmaceutical, Inc. purchases Prosensa Holding NV

Details Hidden

BioMarin Pharmaceutical, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Auditor

Advised onBioMarin Pharmaceutical, Inc. issued USD Common Stock

Auditor

Advised onBioMarin Pharmaceutical, Inc. issued USD Common Stock

Underwriter

Advised onBioMarin Pharmaceutical, Inc. issued USD Common Stock

Associate

Advised onBioMarin Pharmaceutical, Inc. issued USD Common Stock

Professional

Advised onBioMarin Pharmaceutical, Inc. issued USD Common Stock

Co-Chair, Capital Markets Practice

Advised onBioMarin Pharmaceutical, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Consultant

Venture Partner at Clarus Ventures LLC

Senior Advisor

Co-Founder at Rapidscan Pharma Solutions, Inc.

Clients

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Key Stats and Financials As of 2019
Market Capitalization
$15.8B
Total Enterprise Value
$15.3B
Earnings Per Share
$-0.13
Revenue
$1.69B
Net Profit
$-23.8M
EBITDA
$-8.51M
EBITDAMargin
-0.5%
Total Debt
$910M
Total Equity
$3.12B
Enterprise Value / Sales
9.07x
TEVNet Income
-641.29x
Debt TEV
0.06x
Three Year Compounded Annual Growth Rate Of Revenue
14.93%
Non-Profit Donations & Grants
$5,000 - $10K
2019
$50K - $100K
2018
$10K - $50K
2018
Political Donations
$1,500
2014
$1,000
2014
$1,000
2010
Investors
Details Hidden

Investor at Sagimet Biosciences, Inc.

Suppliers
Brooks Automation, Inc. Appliances & Electronics | Chemsford, MA

Brooks is a leading worldwide provider of automation, vacuum, and instrumentation solutions for multiple markets including semiconductor manufacturing, life sciences, and clean energy. Our technologies, engineering competencies, and breadth of global services provide customers speed to market, high uptime, and rapid response, which equate to superior value in their mission-critical environments. Since 1978, Brooks has been a leading partner to the global semiconductor manufacturing market. Through product development initiatives and strategic acquisition, we have expanded our reach to meet the needs of customers in the life sciences industry, analytical and research fields, and clean energy markets. When optimal productivity and high availability are factors for success, customers across the globe turn to Brooks. Brooks is a public company listed on the NASDAQ stock exchange under the symbol BRKS

Cambridge Cognition Holdings Plc Hospitals & Patient Services | Bottisham, United Kingdom

Cambridge Cognition Holdings Plc is a neuroscience digital health company, which engages in the development of digital health products to better understand, detect, and treat conditions affecting brain health. It operates through the following segments: Software, Services, and Hardware. The company's products include drug development, cognitive research, and healthcare technology. The company was founded on September 12, 2012 and is headquartered in Cambridge, the United Kingdom.

Invitae Corp. Medical Support Services | San Francisco, California

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Competitors
Moderna, Inc. Biotechnology - Cambridge, Massachusetts

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Synlogic, Inc. Biotechnology - Cambridge, MA

Synlogic, Inc. is a clinical-stage biopharmaceutical company. It engages in drug discovery and development of synthetic biotic medicines. The firm focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Awards & Honors
Rank #7
2014
Forbes - World's 100 Most Innovative Companies
Sponsored by Forbes Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by BioMarin Pharmaceutical, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of BioMarin Pharmaceutical, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and BioMarin Pharmaceutical, Inc..